RESUMEN
OBJECTIVE: Non-small cell lung cancer (NSCLC) is one of the most common and deadly tumors in the world. LncRNA FAS-AS1 was abnormally expressed in various cancers, such as non-small cell lung cancer. However, the underlying mechanism of FAS-AS1 in NSCLC remains to be elucidated. MATERIALS AND METHODS: The levels of FAS-AS1 and miR-19a-5p were measured using qRT-PCR in NSCLC cells. MTT and cell colony formation assays were performed to detect cell proliferative capacity. Transwell assay was carried out to measure cell migration and invasion. The relationship between FAS-AS1 and miR-19a-5p was confirmed using Luciferase reporter assay. Xenograft tumor experiment was conducted to detect the tumor growth in vivo. RESULTS: FAS-AS1 was remarkably down-regulated in NSCLC cells. FAS-AS1 inhibited cell proliferation, migration, and invasion in NSCLC cells. Additionally, FAS-AS1 directly targeted miR-19a-5p and negatively regulated the expression of miR-19a-5p in NSCLC cells. Furthermore, FAS-AS1 overexpression restored the promotion of miR-19a-5p overexpression on proliferation, migration, and invasion of NSCLC cells. Additionally, suppression of FAS-AS1 abrogated the inhibitory effects of miR-19a-5p knockdown on the progression of NSCLC. FAS-AS1 suppressed the tumor growth in vivo. CONCLUSIONS: FAS-AS1 suppressed cell proliferation, migration, and invasion by sponging miR-19a-5p in NSCLC, indicating that FAS-AS1 might be a potential biomarker and therapeutic target for NSCLC.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Neoplasias Pulmonares/metabolismo , MicroARNs/metabolismo , ARN Largo no Codificante/metabolismo , Receptor fas/metabolismo , Animales , Carcinoma de Pulmón de Células no Pequeñas/patología , Células Cultivadas , Humanos , Neoplasias Pulmonares/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , MicroARNs/genética , Neoplasias Experimentales/metabolismo , Neoplasias Experimentales/patología , ARN Largo no Codificante/genética , Receptor fas/genéticaRESUMEN
UNLABELLED: Revised manuscript accepted for publication March 5, Objectives: The purpose of this study was to determine the potential of cancer testis antigen OY-TES-1 as a vaccine for ovarian cancer (OC). MATERIALS AND METHODS: A tissue microarray (TMA) containing 107 samples from OC tissues and 48 samples from OC adjacent tissues was analyzed by immunohistochemistry with the OY-TES-1 polyclonal antibody. The correlation between OY-TES-1 and clinic pathological traits of OC was statistically analyzed. RESULTS: The expression of OY-TES-1 protein was found in 81% (87/107) of OC tissues and 56% (27/48) of OC adjacent tissues. The immunostaining intensity of OY-TES-1 in OC tissues was significantly higher than that in OC adjacent tissues tested (p = 0.040). OC adjacent tissues only demonstrated lower immunostaining intensity, whereas some of OC tissues presented higher immunostaining intensity and majority showed the heterogeneity of protein distribution. There was no statistically significant correlation found between OY-TES-1 expression and any other clinicopathological traits such as age, FIGO stage, pathological grade, and histological type. CONCLUSIONS: OY-TES-1 was expressed in OC tissues with a high proportion, and some of OC tissues presented OY-TES-1 expression in high level vs OC adjacent tissues. OY-TES-1 could be an attractive target for immunotherapy for OC in the future.
